Serum Amyloid A1/Toll-Like Receptor-4 Axis, an Important Link between Inflammation and Outcome of TBI Patients
Authors:
- Víctor Farré-AlinsVFVíctor Farré-Alins
- Alejandra Palomino-AntolínAPAlejandra Palomino-Antolín
- Paloma Narros-FernándezPNPaloma Narros-Fernández
- Ana Belen Lopez-RodriguezAna Belen Lopez-Rodriguez
- Céline Decouty-PerezCDCéline Decouty-Perez
- Alicia Muñoz-MonteroAMAlicia Muñoz-Montero
- Jorge Zamorano-FernándezJorge Zamorano-Fernández
- Beatriz Mansilla-FernándezBMBeatriz Mansilla-Fernández
- Javier Giner-GarcíaJGJavier Giner-García
- Pablo García-FeijooPGPablo García-Feijoo
- Miguel Sáez-AlegreMSMiguel Sáez-Alegre
- Alexis J. Palpán-FloresAPAlexis J. Palpán-Flores
Open Access
- 25 May 2021
- journal article
- research article
- Published by MDPI AG in Biomedicines
- Vol. 9 (6) , 599
Abstract
Traumatic brain injury (TBI) is one of the leading causes of mortality and disability worldwide without any validated biomarker or set of biomarkers to help the diagnosis and evaluation of the evolution/prognosis of TBI patients. To achieve this aim, a deeper knowledge of the biochemical and pathophysiological processes triggered after the trauma is essential. Here, we identified the serum amyloid A1 protein-Toll-like receptor 4 (SAA1-TLR4) axis as an important link between inflammation and the outcome of TBI patients. Using serum and mRNA from white blood cells (WBC) of TBI patients, we found a positive correlation between serum SAA1 levels and injury severity, as well as with the 6-month outcome of TBI patients. SAA1 levels also correlate with the presence of TLR4 mRNA in WBC. In vitro, we found that SAA1 contributes to inflammation via TLR4 activation that releases inflammatory cytokines, which in turn increases SAA1 levels, establishing a positive proinflammatory loop. In vivo, post-TBI treatment with the TLR4-antagonist TAK242 reduces SAA1 levels, improves neurobehavioral outcome, and prevents blood–brain barrier disruption. Our data support further evaluation of (i) post-TBI treatment in the presence of TLR4 inhibition for limiting TBI-induced damage and (ii) SAA1-TLR4 as a biomarker of injury progression in TBI patients.Keywords
Funding Information
- Fundación Mutua Madrileña (2016)
- Instituto de Salud Carlos III (CP14/00008; CPII19/00005; PI16/00735; PI19/00082; PI18/01387)
This publication has 40 references indexed in Scilit:
- Revisiting Traumatic Brain Injury: From Molecular Mechanisms to Therapeutic InterventionsBiomedicines, 2020
- Traumatic Brain InjuryMedical Clinics of North America, 2020
- The immunological response to traumatic brain injuryJournal of Neuroimmunology, 2019
- TLR4 signal ablation attenuated neurological deficits by regulating microglial M1/M2 phenotype after traumatic brain injury in miceJournal of Neuroimmunology, 2017
- Pathophysiology of Traumatic Brain InjuryPhysical Medicine and Rehabilitation Clinics of North America, 2017
- Clinical evidence of inflammation driving secondary brain injuryJournal of Trauma and Acute Care Surgery, 2015
- A Comparative Review of Toll-Like Receptor 4 Expression and Functionality in Different Animal SpeciesFrontiers in Immunology, 2014
- Different TLR4 expression and microglia/macrophage activation induced by hemorrhage in the rat spinal cord after compressive injuryJournal of Neuroinflammation, 2013
- The pathophysiology of traumatic brain injury at a glanceDisease Models & Mechanisms, 2013
- Role of Toll-Like Receptors in Pathogen RecognitionClinical Microbiology Reviews, 2003